Why the study?
Does saxagliptin reduce ischemic events in patients with Type 2 Diabetes Mellitus?
Does saxagliptin reduce ischemic events in patients with Type 2 Diabetes Mellitus?
Saxagliptin does not reduce ischemic events in patients with type 2 diabetes but increases the risk of hospitalization for heart failure.
No takes yet. Share an insight, caveat, or question.
No ischemic benefit with saxagliptin in T2DM; confirms neutral CV ischemic safety with HF hospitalization signal.
Scirica et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: